Granulocyte colony-stimulating factor – why it is worth to use filgrastim?

2020 ◽  
Vol 13 (3) ◽  
pp. 285-288
Author(s):  
Natalia Ścirka ◽  
Tomasz Kubiatowski
Keyword(s):  
Secondary Prevention ◽  
Side Effect ◽  
Common Side Effect ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Primary And Secondary Prevention ◽  
Mortality Factors ◽  
Stimulating Factor ◽  
Treatment Related Mortality ◽  
Related Mortality

Neutropenia fever is one of the most common side effect of chemotherapy and might lead to severe complications and death. The use of granulocyte colony-stimulating factors in primary and secondary prevention of neutropenia fever leads to reduction in hospitalization time and significantly affects the decrease in treatment-related mortality. Factors stimulating granulocyte colonies prevent the need to reduce the dose of the cytostatics and to extend the intervals between the treatment cycles, which increases the effectiveness of therapy.

Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor in the primary and secondary prevention of chemotherapy-induced neutropenia in patients with lymphoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e20061-e20061
Author(s):  
Meifeng Tu ◽  
Jun Zhu ◽  
Yuqin Song
Keyword(s):  
Secondary Prevention ◽  
Primary Group ◽  
Granulocyte Colony Stimulating Factor ◽  
Efficacy And Safety ◽  
Colony Stimulating Factor ◽  
Primary And Secondary Prevention ◽  
Open Label ◽  
Significant Difference ◽  
Chemotherapy Induced Neutropenia ◽  
Stimulating Factor

e20061 Background: To evaluate the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF, brand name: Jinyouli) in the primary and secondary prevention of chemotherapy-induced neutropenia in patients with lymphoma. Methods: This single-center, one-arm and open-label clinical study enrolled 119 patients with lymphoma in Peking University Cancer Hospital & Institute from May 2016 to December 2018. Patients ≥45 kg received a single dose of PEG-rhG-CSF for 6mg, < 45kg for 3mg, subcutaneous injection once in 24-48 h after chemotherapy. Results: 119 lymphoma patients, including 60 primary and 59 secondary prevention patients, underwent a total of 427 cycles of chemotherapy. The overall incidence of febrile neutropenia (FN) was 6.32% (27/427), with rates of 5.39% and 7.17% in the primary and secondary prevention groups, respectively. There was no significant difference between two groups ( P> 0.05).The incidence of FN was significantly lower in the second cycle than in the first cycle in both the primary and secondary prevention groups ( In the primary group: cycle 1 vs. cycle 2: 15.00% vs. 2.22%, respectively, P= 0.027; In the secondary group: cycle 1 vs. cycle 2: 16.95% vs. 5.08%, respectively, P= 0.040). The overall incidence of grade Ⅳ neutropenia was 13.58% (58/427), with rates of 8.82% and 17.94% in the primary and secondary prevention groups, respectively. There was a significant difference between two groups ( P= 0.006). The incidence of grade Ⅳ neutropenia was significantly lower in the second cycle than in the first cycle (In the primary group: cycle 1 vs. cycle 2: 25.00% vs. 4.44%, respectively, P= 0.005; In the secondary group: cycle 1 vs. cycle 2: 47.46% vs. 11.86%, respectively, P< 0.001). The main treatment-related adverse event was bone pain, with an incidence of 2.52% (3/119). Conclusions: PEG-rhG-CSF can effectively reduce the incidence of FN and neutropenia with good safety in patients with lymphoma after chemotherapy. Primary prevention can significantly reduce the risk of grade IV neutropenia in all chemotherapy cycles compared with the secondary prevention. Clinical trial information: NCT02905916 .

scholarly journals Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children’s Oncology Group

Blood ◽  
2013 ◽  
Vol 121 (18) ◽  
pp. 3573-3577 ◽  
Author(s):  
Lillian Sung ◽  
Richard Aplenc ◽  
Todd A. Alonzo ◽  
Robert B. Gerbing ◽  
Thomas Lehrnbecher ◽  
...  
Keyword(s):  
Supportive Care ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Oncology Group ◽  
Infection Rates ◽  
Key Points ◽  
Pediatric Aml ◽  
Stimulating Factor ◽  
Related Mortality ◽  
Systemic Antibacterial

Key Points Systemic antibacterial and granulocyte colony-stimulating factor prophylaxis appear to reduce bacterial infection rates. Mandatory hospitalization during profound neutropenia did not reduce infection or significantly reduce nonrelapse-related mortality.

Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)

2020 ◽  
Vol 106 (4) ◽  
pp. 273-280
Author(s):  
Antonino C. Tralongo ◽  
Andrea Antonuzzo ◽  
Paolo Pronzato ◽  
Andrea Sbrana ◽  
Marianna Turrini ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Side Effect ◽  
Hospital Admissions ◽  
Medical Oncology ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Patients With Cancer ◽  
Probability Of Death ◽  
Chemotherapy Induced Neutropenia ◽  
Stimulating Factor

Neutropenia is the most frequent side effect of commercially available myelosuppressive drugs and its most significant complication is febrile neutropenia. It is associated with increased hospital admissions and higher probability of death. Prophylaxis with the administration of granulocyte colony-stimulating factor can prevent neutropenia caused by anticancer drugs. The correct administration of these drugs and the management of febrile neutropenia are extremely important in the treatment of patients with cancer.

scholarly journals Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy

Blood ◽  
1989 ◽  
Vol 74 (8) ◽  
pp. 2644-2651 ◽  
Author(s):  
A Lindemann ◽  
F Herrmann ◽  
W Oster ◽  
G Haffner ◽  
W Meyenburg ◽  
...  
Keyword(s):  
Serum Levels ◽  
Common Side Effect ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Advanced Malignancy ◽  
Once Daily ◽  
Dose Levels ◽  
Dose Dependent Increase ◽  
Dose Dependent ◽  
Stimulating Factor

The effect of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematologic parameters was evaluated in a phase I clinical study in 18 patients with advanced malignancy. G-CSF was administered once daily as a 30-minute infusion for 14 days; three patients each were treated at increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A transient decrease in neutrophil and monocyte counts was observed immediately after the G-CSF infusion, followed by a dose-dependent increase of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastase, were markedly elevated during therapy. A dose-dependent depression of platelet counts occurred in the second third of the treatment course, followed by a spontaneous recovery despite continuing therapy. G-CSF was well-tolerated; minor to moderate bone pain was the most common side effect. The primary course of the malignant diseases studied was not significantly altered. G-CSF appears to be an appropriate means to selectively increase the number of functionally competent polymorphonuclear phagocytes.

Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation

2006 ◽  
Vol 24 (33) ◽  
pp. 5207-5215 ◽  
Author(s):  
Allison Dekker ◽  
Sean Bulley ◽  
Joseph Beyene ◽  
L. Lee Dupuis ◽  
John J. Doyle ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Colony Stimulating Factor ◽  
Stimulating Factor ◽  
Treatment Related Mortality ◽  
Related Mortality

Purpose The primary objective of our meta-analysis was to determine whether prophylactic hematopoietic colony-stimulating factors (CSFs) after hematopoietic autologous and allogeneic stem-cell transplantation (SCT) reduced documented infections. Our secondary objectives were to determine whether prophylactic CSFs affected other outcomes including parenteral antibiotic therapy duration, infection-related mortality, graft-versus-host disease (GVHD), or treatment-related mortality. Methods We included studies if there was random assignment between CSFs and placebo/no therapy and CSFs were given after SCT and before recovery of neutrophils. From 3,778 reviewed study articles, 34 were included based on predefined inclusion criteria. All analyses were conducted using a random effects model. Results CSFs reduced the risk of documented infections (relative risk [RR] 0.87; 95% CI, 0.76 to 1.00; P = .05) and duration of parenteral antibiotics (weighted mean difference, −1.39 days, 95% CI, −2.56 to −0.22; P = .02) but did not reduce infection-related mortality (RR, 0.76; 95% CI, 0.41 to 1.44; P = .4). CSFs did not increase grade 2 to 4 acute GVHD (RR, 1.03; 95% CI, 0.81 to 1.31; P = .8) or treatment-related mortality (RR, 1.00; 95% CI, 0.78 to 1.29; P = .98). Conclusion CSFs were associated with a small reduction in the risk of documented infections but did not affect infection or treatment-related mortality.

Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy

Blood ◽  
1989 ◽  
Vol 74 (8) ◽  
pp. 2644-2651 ◽  
Author(s):  
A Lindemann ◽  
F Herrmann ◽  
W Oster ◽  
G Haffner ◽  
W Meyenburg ◽  
...  
Keyword(s):  
Serum Levels ◽  
Common Side Effect ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Advanced Malignancy ◽  
Once Daily ◽  
Dose Levels ◽  
Dose Dependent Increase ◽  
Dose Dependent ◽  
Stimulating Factor

Abstract The effect of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematologic parameters was evaluated in a phase I clinical study in 18 patients with advanced malignancy. G-CSF was administered once daily as a 30-minute infusion for 14 days; three patients each were treated at increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A transient decrease in neutrophil and monocyte counts was observed immediately after the G-CSF infusion, followed by a dose-dependent increase of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastase, were markedly elevated during therapy. A dose-dependent depression of platelet counts occurred in the second third of the treatment course, followed by a spontaneous recovery despite continuing therapy. G-CSF was well-tolerated; minor to moderate bone pain was the most common side effect. The primary course of the malignant diseases studied was not significantly altered. G-CSF appears to be an appropriate means to selectively increase the number of functionally competent polymorphonuclear phagocytes.

Granulocyte-colony stimulating factor for the treatment of neurodegenerative diseases

2008 ◽  
Vol 35 (S 01) ◽  
Author(s):  
T Frank ◽  
K Meuer ◽  
C Pitzer ◽  
J Schulz ◽  
M Bähr ◽  
...  
Keyword(s):  
Neurodegenerative Diseases ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor
Sign in / Sign up

Export Citation Format

Share Document